227 related articles for article (PubMed ID: 11794886)
41. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
[TBL] [Abstract][Full Text] [Related]
42. Raloxifene and endometrial cancer.
Sismondi P; Biglia N; Ujcic E; Ponzone R; Roagna R
Tumori; 2001; 87(5):S18-9. PubMed ID: 11765199
[No Abstract] [Full Text] [Related]
43. [What can we expect of raloxifene in the treatment of postmenopausal osteoporosis--views of a gynecologist].
Chmel R; Rob L; Strnad P
Ceska Gynekol; 2002 Jul; 67(4):187-91. PubMed ID: 12373918
[TBL] [Abstract][Full Text] [Related]
44. Effect of raloxifene on sexual function in older postmenopausal women with osteoporosis.
Modugno F; Ness RB; Ewing S; Cauley JA
Obstet Gynecol; 2003 Feb; 101(2):353-61. PubMed ID: 12576261
[TBL] [Abstract][Full Text] [Related]
45. Raloxifene for breast cancer prevention.
Plouffe L
JAMA; 2001 Apr; 285(16):2079. PubMed ID: 11311092
[No Abstract] [Full Text] [Related]
46. [Selective estrogen receptor modulators (SERMs)].
Chaki O
Nihon Rinsho; 2015 Oct; 73(10):1673-81. PubMed ID: 26529929
[TBL] [Abstract][Full Text] [Related]
47. An update on raloxifene.
Draper MW
Int J Gynecol Cancer; 2006; 16 Suppl 2():502-3. PubMed ID: 17010057
[No Abstract] [Full Text] [Related]
48. The role of SERMs in the management of postmenopausal osteoporosis.
Compston J
J Endocrinol Invest; 1999 Sep; 22(8):646-52. PubMed ID: 10532253
[No Abstract] [Full Text] [Related]
49. Role of antiestrogens and aromatase inhibitors in breast cancer treatment.
Bentrem DJ; Jordan VC
Curr Opin Obstet Gynecol; 2002 Feb; 14(1):5-12. PubMed ID: 11801870
[TBL] [Abstract][Full Text] [Related]
50. [Evidence of raloxifene on postmenopausal osteoporosis].
Okano H
Nihon Rinsho; 2007 Nov; 65 Suppl 9():374-80. PubMed ID: 18161135
[No Abstract] [Full Text] [Related]
51. The selective estrogen receptor modulators in breast cancer prevention.
Li F; Dou J; Wei L; Li S; Liu J
Cancer Chemother Pharmacol; 2016 May; 77(5):895-903. PubMed ID: 26787504
[TBL] [Abstract][Full Text] [Related]
52. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Pickar JH; Komm BS
Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
[TBL] [Abstract][Full Text] [Related]
53. Report examines strategies for reducing breast cancer risk.
Miller JL
Am J Health Syst Pharm; 1999 Jul; 56(13):1298. PubMed ID: 10683123
[No Abstract] [Full Text] [Related]
54. Estrogen, selective estrogen receptor modulation, and coronary heart disease: something or nothing.
Jordan VC
J Natl Cancer Inst; 2001 Jan; 93(1):2-4. PubMed ID: 11136828
[No Abstract] [Full Text] [Related]
55. The role of selective estrogen receptor modulators (SERMs) in postmenopausal health.
Draper MW
Ann N Y Acad Sci; 2003 Nov; 997():373-7. PubMed ID: 14644844
[TBL] [Abstract][Full Text] [Related]
56. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants.
Lippman ME; Krueger KA; Eckert S; Sashegyi A; Walls EL; Jamal S; Cauley JA; Cummings SR
J Clin Oncol; 2001 Jun; 19(12):3111-6. PubMed ID: 11408508
[TBL] [Abstract][Full Text] [Related]
57. Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects.
Muchmore DB
Oncologist; 2000; 5(5):388-92. PubMed ID: 11040275
[TBL] [Abstract][Full Text] [Related]
58. Selective oestrogen receptor modulation: molecular pharmacology for the millennium.
Levenson AS; Jordan VC
Eur J Cancer; 1999 Dec; 35(14):1974-85. PubMed ID: 10711240
[TBL] [Abstract][Full Text] [Related]
59. Beyond raloxifene for the prevention of osteoporosis and breast cancer.
Jordan VC
Br J Pharmacol; 2007 Jan; 150(1):3-4. PubMed ID: 17115068
[TBL] [Abstract][Full Text] [Related]
60. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.
Martino S; Costantino J; McNabb M; Mershon J; Bryant K; Powles T; Secrest RJ
Oncologist; 2004; 9(2):116-25. PubMed ID: 15047916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
